Asset
ARIPIPRAZOLE LAUROXIL
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01626456 | phase3 | completed | 2012-06-01 | 2015-04-01 | Alkermes, Inc. | A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) |
| NCT01493726 | phase1 | completed | 2011-12-01 | 2013-06-01 | Alkermes, Inc. | A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia |
| NCT01469039 | phase3 | completed | 2011-12-01 | 2014-01-01 | Alkermes, Inc. | A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia |
| NCT01895452 | phase3 | completed | 2013-07-01 | 2016-06-01 | Alkermes, Inc. | An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) |
FDA applications (0)
This company has no applications containing this asset.